Investors / United States / Monograph Capital
Monograph Capital
Venture capital · Fort Worth, TX, United States · North America
Monograph Capital founds and supports life sciences companies. The firm has offices in Fort Worth, London and San Francisco.
Invests inHealthcare & Biotech
In its own wordslife sciencesbiotechhealthcare
Your fit with Monograph Capital
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsMonograph Capital lists 5 checked portfolio companies on its own site and is named in 6 funding rounds. Its most frequent entry is Series A, 80% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 60% of its companies are based in United Kingdom. It invests most often alongside Forbion, LifeArc Ventures and 5AM Ventures.
Counts come from funding rounds that name Monograph Capital, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Entry stage
share of companies by the stage of its first roundMonograph Capital does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 80% |
| Series B | 20% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 4 | 0 |
| '26 | 2 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 4th | 5 companies |
| Recent activity | 76th | 3 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 52th | 0% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 42th | 2 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Forbion | 2 |
| LifeArc Ventures | 2 |
| 5AM Ventures | 1 |
| BGF | 1 |
| Canaan | 1 |
| F-Prime Capital | 1 |
| Frazier Life Sciences | 1 |
| General Catalyst | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers5100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare Monograph Capital head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Monograph Capital| Date | Company | Stage |
|---|---|---|
| 24 Jun 2026 | Series A | |
| 7 Jan 2026 | Series B | |
| 11 Dec 2025 | Series A | |
| 22 Oct 2025 | Series A | |
| 17 Mar 2025 | Series A |
Round details for Monograph Capital
Amounts, full round histories and every co-investor in Monograph Capital's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
5 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Elevara Medicines develops treatments for rheumatoid arthritis | Healthcare & Biotech | Oct 2025Series A | Funding round | |
| Maxion Therapeutics creates protein therapeutics for treating diseases using its KnotBody technology | Healthcare & Biotech | Mar 2025Series A | Funding round | |
| Nocion Therapeutics is developing a new class of treatment for chronic cough and other diseases of sensory neuron hypersensitivity | Healthcare & Biotech | Jan 2026Series B | Funding round | |
| Prolynx is developing a next-generation portfolio of extended-duration therapeutics designed for once-monthly and once-quarterly dosing for obesity and related metabolic conditions. | Healthcare & Biotech | Dec 2025Series A | Funding round | |
| RQ Bio discovers and develops long-acting monoclonal antibodies against seasonal influenza | Healthcare & Biotech | Jun 2026Series A | Funding round |
About this data
site last read 5 Nov 2026- Site
- monograph.bio
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 17 Mar 2025
- Companies checked
- 5
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Monograph Capital's profile as data
Pull Monograph Capital's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/monograph.bio
# also
GET /v1/firms/monograph.bio/portfolio
GET /v1/firms/monograph.bio/coinvestors
GET /v1/firms/monograph.bio/news